Clinical study on Feilike Mixture combined with recombinant human interferon α2b in treatment of pediatric respiratory syncytial virus pneumonia
Objective To explore the clinical effect of Feilike Mixture combined with recombinant human interferon α2b in treatment of pediatric respiratory syncytial virus pneumonia.Methods Children(158 cases)with pediatric respiratory syncytial virus pneumonia in Shengjing Hospital of China Medical University from July 2020 to July 2023 were randomly divided into control and treatment group,and each group had 79 cases.Children in the control group were nebulization inhalation administered with Recombinant Human Interferon α2b Injection for 15 min,100 000 IU/kg diluted to 2 mL with 0.9%sodium chloride injection,once daily,oxygen flow rate was 6 L/min.Children in the treatment group were po administered with Feilike Mixture on the basis of the control group,10 mL/time,three times daily.Children in two groups were treated for 7 d.After treatment,the clinical evaluations were evaluated,the disappearance time of symptoms and signs and respiratory syncytial virus conversion time,the PCRAES scores,and the levels of RR,Ti/Te,PTEF,HMGB1,IFN-γ,ECP and IL-6 in two groups before and after treatment were compared.Results After treatment,the total effective rate in the treatment group(97.47%)was significantly higher than that in the control group(89.87%),and the difference between the two groups was statistically significant(P<0.05).After treatment,the disappearance time of symptoms and signs and the time of respiratory syncytial virus turning negative in the treatment group were significantly shorter than those in the control group(P<0.05).After treatment,the tidal breathing pulmonary function indicators RR,Ti/Te and PTEF in two groups were significantly lower than before treatment(P<0.05),and which in the treatment group were significantly lower than those in the control group(P<0.05).After treatment,the PCRAES score and serum HMGB1,ECP,and IL-6 levels in two groups were significantly lower than before treatment in the same group,while the serum IFN-γ levels increased significantly(P<0.05),and the levels of these indicators in the treatment group were significantly better than those in the control group(P<0.05).Conclusion Recombinant human interferon α2b combined with Feilike Mixture is safe in treatment of pediatric respiratory syncytial virus pneumonia.It can effectively accelerate the clearance of respiratory syncytial virus and control of symptoms and signs,inhibit inflammatory reactions,and promote the improvement of lung function.
Feilike MixtureRecombinant Human Interferon α2b Injectionrespiratory syncytial viruspneumoniaPCRAESPTEFECPHMGB1
NETL
NSTL
万方数据
